Abstract
Immune checkpoint inhibition is a new and promising therapy approved for the treatment of various malignancies. Pembrolizumab is a potent tumour suppressor that acts by upregulating the immune system to recognise cancer cells, which may result in disrupted self-tolerance. We describe a case of seronegative ocular myasthenia gravis after treatment with pembrolizumab for metastatic melanoma. Her bilateral ptosis was refractory to conventional treatment, and she remains functionally blind as a result. As the availability and use of immunotherapy continues to rise, awareness of its immune-related adverse effects (irAEs) is crucial for clinicians.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
